Fluarix Exhibited Immunogenicity Adults

FLUARIX QUADRIVALENT was studied in a randomized, double-blind (2 arms), open-label (1 arm), active-controlled, immunogenicity, safety, and non-inferiority trial. Subjects aged 18 years and older in the according-to-protocol cohort received FLUARIX QUADRIVALENT (n=1809) or 1 of 2 formulations of a comparator trivalent influenza vaccine (TIV) (FLUARIX TIV-1, n=608 or TIV-2, n=534), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Immune responses were evaluated in sera obtained 21 days after administration of FLUARIX QUADRIVALENT or the comparators.¹